
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences is making strong and steady progress in its goal of improving healthcare by making ECGs more effective for early detection of heart disease through AI technology. The company has shown impressive expense control, has multiple revenue streams in place for its AI-enabled ECG platform, and is on track for FDA approval and significant revenues from the over 100 million ECG tests performed annually in the US. The key risks for the company include balancing its balance sheet/liquidity, navigating regulatory approvals, and obtaining suitable reimbursement, but overall its potential for success and high market demand make it an attractive investment opportunity.
Bears say
HeartSciences is experiencing significant operating expenses, with a current total of $2.1 million, and a predicted increase in the future due to equity financing. While the company reported a slight beat in Q2 FY26, their real strength lies in their key device submission and upgrade to their AI-ECG software platform, which could potentially drive long-term growth and profitability for the company. However, given the uncertain nature of the medical technology industry and the competitive landscape, a negative outlook is justified as it is unclear if the company will be able to successfully penetrate the market and generate significant revenues in the near future.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares